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ABSTRACT 
Viruses transmitted by arthropods (arboviruses) are the etiological agents of several human diseases with world-
wide distribution; including dengue (DENV), zika (ZIKV), yellow fever (YFV), and chikungunya (CHIKV) vi-
ruses. These viruses are especially important in tropical and subtropical regions; where, ZIKV and CHIKV are 
involved in epidemics worldwide, while the DENV remains as the biggest problem in public health. Factors, such 
as, environmental conditions promote the distribution of vectors, deficiencies in health services, and lack of effec-
tive vaccines, guarantee the presence of these vector-borne diseases. Treatment against these viral diseases is only 
palliative since available therapies formulated lack to demonstrate specific antiviral activity and vaccine candidates 
fail to demonstrate enough effectiveness. The use of natural products, as therapeutic tools, is an ancestral practice 
in different cultures. According to WHO 80 % of the population of some countries from Africa and Asia depend 
on the use of traditional medicines to deal with some diseases. Molecular characteristics of these viruses are im-
portant in determining its cellular pathogenesis, emergence, and dispersion mechanisms, as well as for the devel-
opment of new antivirals and vaccines to control strategies. In this review, we summarize the current knowledge 
of the molecular structure and replication mechanisms of selected arboviruses, as well as their mechanism of entry 
into host cells, and a brief overview about the potential targets accessed to inhibit these viruses in vitro and a 
summary about their treatment with natural extracts from plants. 
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INTRODUCTION 
Arbovirus (arthropod-borne viruses) is a 
group that comprises viruses which belong to 
four different families: Togaviridae, Reoviri-
dae, Flaviviridae, and Bunyaviridae, these are 
characterized by a cycle of transmission be-
tween vertebrate hosts and arthropod vectors 
and are responsible for the development of 
emerging and re-emerging diseases world-
wide in recent decades (Hubálek et al., 2014; 
Weaver and Reisen, 2010). The Aedes (Steg-
omyia) aegypti (L.) and Aedes (Stegomyia) 
albopictus (Skuse) mosquitoes (Diptera: Cu-
licidae) are primary vectors for arboviruses 
such as dengue, yellow fever, zika and 
chikungunya viruses guaranteeing their per-
manence and circulation in the population 
(Leta et al., 2018). Some of these viruses are 
involved in epidemics in the African conti-
nent and Latin America, with possible urban 
cycles (Bhatt et al., 2013; Colón-González et 
al., 2017; Higuera and Ramírez, 2019; Litvoc 
et al., 2018).  
According to the Pan American Health 
Organization reports, the vector-borne dis-
eases are ordered by frequency and preva-
lence in the following manner: 1st place den-
gue, with cases in almost all of the countries 
of the American region; 2nd chikungunya; 3rd 
zika, which is then followed by Malaria, Cha-
gas, Leishmaniasis and Yellow fever (PAHO-
CHA-IR, 2016).  
It is important, from the public health 
point of view, to deepen the studies related to 
dengue virus (DENV), yellow fever virus 
(YFV), zika virus (ZIKV) and chikungunya 
virus (CHIKV) that lead to the development 
of effective, specific and economic therapeu-
tic strategies for their control.  
In Latin America, one of the most im-
portant arbovirus families is Flaviviridae, 
which comprises more than 70 species. This 
family is constituted by four genera: Hepaci-
virus, one of the representatives being the 
hepatitis C virus (HCV); Pestivirus, for which 
Bovine viral diarrhea virus (BVDV) is a rep-
resentative; Pegivirus, to which belongs the 
viruses GBV-A, GBV-D, GBV-C, among 
others; and the genus Flavivirus, which is one 
of the largest genus, and several medically 
important species such as YFV, DENV, and 
ZIKV, among other arboviruses, belong to 
this genus (Blitvich and Firth, 2017).  
One of the first species described in the 
genus Flavivirus was the YFV; it was isolated 
for the first time in 1927 in Ghana. The esti-
mated number of cases of YFV in Africa and 
Latin America are about 120,000 per year, 
with approximately 45,000 deaths/year. The 
clinical manifestations range from an asymp-
tomatic disease (around 50 % of the cases) to 
a very severe form of the disease, with 20 % 
mortality rate (Litvoc et al., 2018). Currently, 
its prevention has been achieved via the 17D 
vaccine, however it still remains a public 
health problem, due to the current outbreaks 
in endemic and non-endemic areas (Douam 
and Ploss, 2018), which raised interest in re-
lation to the potential impact of YFV into 
non-endemic countries, where usually people 
do not get vaccinated. 
Another related Flavivirus is dengue vi-
rus, one of the main public health problems in 
tropical and subtropical regions. There is an 
alarming estimation of 390 million of dengue 
infections per year, with distribution in almost 
all countries of the American region. The clin-
ical manifestations vary from asymptomatic 
or mild fever to severe dengue (hemorrhagic 
and shock syndromes), with a mortality rate 
of up to 20 % among the patients with severe 
dengue (Bhatt et al., 2013; PAHO-CHA-IR, 
2016). Dengue fever may be caused by four 
different serotypes: DENV1, DENV2, 
DENV3, or DENV4 (Kostyuchenko et al., 
2013), where the immunity towards the in-
fecting serotype is life-long; however, severe 
forms of the disease may occur after the sec-
ond or subsequent infection caused by a dif-
ferent dengue virus serotype, since the cross-
protection against other serotypes is limited 
(Martina et al., 2009; Torres et al., 2017). Re-
cently a fifth serotype has been published, 
however it seems to be limited to the sylvatic 
cycle only (Mustafa et al., 2015). The devel-
opment of vaccines against dengue has not 
been easy, perhaps due to the genomic varia-
bility of its four serotypes and the complexity 
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of its pathogenesis. Currently there is an ap-
proved vaccine: CYD-TDV (under the com-
mercial name Dengvaxia®), developed by 
Sanofi Pasteur, however there is still no clar-
ity about its safety and efficacy (Malisheni et 
al., 2017; Prompetchara et al., 2019).  
ZIKV is a public health problem since it 
caused a pandemic between 2015 and 2016, 
with more than one million cases reported 
only in Latin America (Hennessey et al., 
2016). Two genotypes have been described 
(African and Asian), based on the phyloge-
netic analysis (Shi and Gao, 2017). Its infec-
tion may be asymptomatic or may present 
acute fever and rash; the reports have associ-
ated the infection with congenital syndromes 
and severe neurological complications 
(Musso and Gubler, 2016). These neurologi-
cal complications can be a consequence of the 
activation of protein complexes involved in 
the proliferation and apoptosis processes of 
glial cells. Although ZIKV presents a mature 
structure similar to other known flaviviral 
structures (Shi and Gao, 2017; Wang et al., 
2017a), some of its clinical manifestation dif-
fers from other flaviviruses. Additionally, the 
genomic divergences among the ZIKV 
strains/isolates can in turn be associated with 
the differential clinical manifestations of the 
infection (Shi and Gao, 2017; Wang et al., 
2017a).  
Another important arbovirus family found 
in Latin America is Togaviridae. The CHIKV 
belongs to this family, and the Alphavirus ge-
nus. Currently there are four genotypes of 
chikungunya reported: The East-Central-
South Africa, West Africa, Asian, and Indian 
Ocean lineage; all of them were named based 
in their geographic distribution. The CHIKV 
has a close relation with more alphaviruses 
such as: The o´nyong’nyong Virus, Rio Ross 
Virus, Mayaro Virus, Barmah Forest Virus 
and the group of Sindbis Virus, all of them are 
known as causative agents of arthritis (Vu et 
al., 2017). Since 1950, CHIKV was found and 
characterized only in East Africa; only in the 
late 1990s and early 2000s, CHIKV remerged 
on a global scale (Ganesan et al., 2017), arriv-
ing to the Americas in 2013 affecting more 
than one million people (Vu et al., 2017). Re-
garding the clinical manifestations, most pa-
tients suffer a self-limited febrile syndrome 
with polyarthritis and rash; however, some 
patients have reported persistent arthralgia 
even for years. Alterations of the central nerv-
ous system such as convulsions, meningoen-
cephalitis, and Guillain-Barré syndrome have 
been reported. Myocarditis, liver failure in pa-
tients with antecedents of chronic liver dis-
ease, endocrine alterations, pancreatitis, and 
respiratory failure have also been reported, 
although less frequently (Simon et al., 2011).  
The prevalence of these viruses is guaran-
teed by the proximity of populations to the 
jungle areas that allows the maintenance of all 
these viruses that move back and forth be-
tween each environment (Figueiredo, 2019), 
this complex situation is probably the cause of 
some of the reemerging epidemics, related to 
some arboviruses. 
Molecular analysis is important to under-
stand the mechanisms by which arboviruses 
cause infectious and remain in nature, as well 
as its pathogenicity and immunogenicity, 
opening a path for new research. This review 
is focused on the genomic structure, replica-
tion mechanisms of some Flavivirus and Al-
phavirus and a summary about their possible 
treatments with natural extracts from plants. 
 
MOLECULAR STRUCTURE OF  
FLAVIVIRUS AND ALPHAVIRUS 
Flaviviruses 
All viruses included in the Flavivirus ge-
nus have some common characteristics: a size 
of 40-60 nanometers; an envelope that is cov-
ering an icosahedral nucleocapsid, which pro-
tects the genetic material; and a single posi-
tive sense RNA strand, which is approxi-
mately 10.000 to 11.000 bases in length. This 
strand has a unique open reading frame 
(ORD) consisting of approximately ~3400 
codons, that encodes for a unique viral poly-
protein (Brinton and Basu, 2015). These vi-
ruses show a type I cap in the 5'-end. The 
presence of a methylation in 5' cap in the 
RNA viral genome has an important role to 
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play in the viral translation/replication pro-
cess and is involved in the evasion of the im-
mune reactions that restrict the viral replica-
tion in the host. Presence of Poly (A) tails at 
3'-termini, in the 5' and 3' terminal regions, 
there are short conserved sequences whose 
functions are still unknown. The Flavivirus 
genome works as a viral mRNA and as a tem-
plate for the synthesis of small RNA chains. 
Its organization is maintained between the 
different genera (Lindenbach and Rice, 2003; 
Brinton and Basu, 2015).  
In the family Flaviviridae, most of the 
members have the typical genome with a sim-
ilar order of genes and some conserved non-
structural proteins (Figure 1). However, they 
diverge notoriously in the cis-acting regula-
tory elements of the RNA located at their 3' 
and 5' ends. For example, the polyproteins 
translated from the genomes of Hepacivirus, 
Pestivirus, and Pegivirus begin with an AUG 
sequence that is found at the 3' end. This is the 
internal ribosome entry site (IRES). On the 
contrary the translated protein of Flavivirus is 
dependent on a type I cap located at the 5' end. 
The genome of the Flaviviridae family is or-
ganized as follows:  
Flavivirus: 5'CAP (I)-5'UTR-C-prm-E-
NS1-NS2A-NS2B-NS3-NS4A-NS4B-NS5-
3'UTR  
The ORF of the Flavivirus encodes for a 
polyprotein which is processed by host and 
viral proteases in three structural proteins, the 
C protein of nucleocapsid, a glycoprotein pre-
cursor of prM membrane, and a glycosylated 
envelope protein E, along with seven non-
structural proteins (NS) viz. NS1, NS2A/B, 
NS3, NS4A, NS4B, and NS5, which are ar-
ranged from terminal N to C. The process of 
proteolysis of the polyprotein of Flavivirus is 
carried out through the combination of four 
different proteases (Bollati et al., 2010). 
Figure 1: Comparison of Flavivirus and Alphavirus genome. (A) The Flavivirus, similar to the Al-
phavirus genus, contain single stranded RNA of positive sense; however, this has a unique open reading 
frame (ORF). In the 5´ end, a type I cap is present and at the 3´ end, a polyadenylation tail is observed. 
A typical genome has a similar order of genes and some conserved non-structural proteins (NS). (B) 
The viruses belonging to the Alphavirus genus possess a genome consisting of a positive sense single 
stranded RNA with two ORFs at the 5´ end. These code for four non-structural protein (nsP1-4). Another 
ORF at the 3´ end, codes for five structural proteins namely, capsid protein (C), envelope glycoproteins 
(E1 and E2), and two small cleavage products (E3 and 6K). 
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Processing of the viral polyprotein 
(1) A host signal peptidase process the anchor 
junctions -C/prM, prM/E, E/NS1, and 
NS4A-“2K”/NS4B. 
(2) The viral NS3 serine protease needs 
NS2B as a cofactor, to process the C-an-
chor junctions of NS2A/NS2B, 
NS2B/NS3, NS3/NS4A, NS4A/"2K", and 
NS4B/NS5. 
(3) The furin of the host, or other furin bind-
ing proteins process the binding between 
pr/M. 
(4) The proteases of the host involved in sep-
arating the NS1/NS2A junction are un-
known.  
Among the structural proteins, the C pro-
tein of nucleocapsid protects and encapsulates 
the genetic material. An envelope glycopro-
teins prM/M creates the superficial structure 
of the virion. The protein prM/M has an im-
portant role in the maintenance of the spatial 
structure of the E protein, which is composed 
of three different structures, envelope domain 
I, II, and III (EDI, EDII, EDIII, respectively), 
connected to the viral membrane (Zhang et 
al., 2017). In YFV, the E protein is highly im-
munogenic and plays a central role in viral 
binding and fusion (Volk et al., 2009).  
EDI forms the central domain of the enve-
lope protein, which establishes the protein di-
rection and its glycosylation sites. The glyco-
sylation domains of EDI are associated with 
the viral production, pH sensitivity and neu-
roinvasiveness in most flaviviruses. Interest-
ingly, ZIKV has a single glycosylation site 
(N154) in the EDI with a longer loop (resi-
dues 145–160) compared to other flaviviruses 
(Kostyuchenko et al., 2013). EDII plays an 
important role in the membrane fusion, and 
EDIII is the main target of the neutralizing an-
tibodies; these proteins are essential in the bi-
ology of the Flavivirus (Shi and Gao, 2017; 
Zhang et al., 2017). The structure of the Do-
main III of YFV differs from the structure of 
other mosquito-transmitted flaviviruses, spe-
cifically in the surface exposed BC loop, since 
it is one amino acid shorter, than even other 
mosquito-borne and non-vector borne vi-
ruses. This change can modify neutralization 
sites and receptor interactions, and therefore, 
the viral pathogenesis (Volk et al., 2009). 
A difference in the amino acid sequence 
of the EDIII region has been reported in the 
DEN4 sylvatic and human strains, which may 
be related to their jump from a sylvatic host to 
a human one (Volk et al., 2007). Therefore, 
this region among Flavivirus shows consider-
able variation. 
The non-structural proteins, modulate in-
tracellular process, such as viral replication, 
assembly, proteolysis, maturation, and regu-
lation of the host immune response and are in-
volved in the evasion of the immune response. 
In the case of evasion of the immune response 
by DENV the following are involved: NS2A, 
NS2B3, NS4A, NS4B and NS5 (Chen et al., 
2017).  
About the non-structural proteins, they 
change in functions and structure between dif-
ferent Flaviviruses. For example, NS1 is a 
highly conserved protein that is encoded ex-
clusively by the members of genus Flavivirus 
and is considered as the major antigenic 
marker during infection. This non-structural 
protein is a dimeric protein with molecular 
weight between 46-55 kDa depending on the 
degree of glycosylation, which is important 
for the efficiency of the viral secretion, repli-
cation, and virulence. Thus, deletion of NS1 
glycosylation sites of DENV and YFV, sig-
nificantly reduce their viral replication. NS1 
can exist as a monomer, dimer (protein con-
nected to the mNS1 membrane) and also as a 
hexamer (secreted protein, sNS1) (Rastogi et 
al., 2016; Chen et al., 2017). A recent study 
shows that the overall structure of NS1 is sim-
ilar among YFV, ZIKV, DENV, and WNV 
(Wang et al., 2017c). NS1 of ZIKV has a di-
versity of electrostatic surface features in the 
host-virus interaction context as well as 
unique dimeric assembly (Song et al., 2016).  
The NS1 function is to activate the Toll-
like receptors (TLRs) and inhibit the comple-
ment system in order to interact with the NS4 
protein. The activation of the TLRs is im-
portant as it leads to the activation of tran-
scription factors and the production of cyto-
kines as a part of the innate immune response. 
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The main receptor for Flaviviridae is TLR3, 
which in turn can modulate the activation of 
dendritic cells, macrophages, and B cells as 
well as triggers the IFN mRNA transcription, 
thus inducing the innate antiviral responses 
(Alayli and Scholle, 2016; Chen et al., 2017). 
Spontaneous mutation resulting in a single 
amino acid substitution in ZIKV NS1 protein 
increased its infectivity in Aedes aegypti mos-
quitoes, which most likely had promoted its 
transmission in the recent epidemic (Liu et al., 
2017).  
In the case of WNV, NS1 reduces the reg-
ulation of the IFN-β and IL-6 transcription 
mediated by TLR3; nonetheless, this inhibi-
tion can be dependent on cell type (Chen et 
al., 2017). It has been reported that the expres-
sion of the WNV, YFV or DENV-2 NS1 pro-
tein, does not alter the TLR3 translation levels 
in two cell lines (HeLa and HEK-293) 
(Baronti et al., 2010). This could indicate that 
the TLR3 pathway is not exclusive in the con-
trol of flaviviruses replication and they pos-
sess other mechanisms for evading the host 
immune response.  
On the other hand, in the dengue virus, 
NS1 anchors the replication complex to the 
host endoplasmic reticulum membrane, and 
interacts directly with NS4B, As a result, 
it plays an important role in the viral replica-
tion process. Furthermore, YFV and DENV 
are associated with hemorrhagic fever, this 
may be due to the increased vascular permea-
bility. However it can be mediated by the NS1 
protein, because it has been shown that its 
binding to heparin sulfate of the endothelial 
glycocalyx layer may alter the capillary per-
meability (Puerta-Guardo et al., 2016). This is 
also relevant in the severe forms of dengue 
since anti-NS1 antibodies join to the surface 
of the endothelial cells and platelets produc-
ing cell damage (Chen et al., 2018). Besides, 
ZIKV NS1, from Asian lineage strains, can be 
involved in the developmental complications 
such as microcephaly in fetuses and also se-
vere neurological manifestations in adults. 
However, currently it is not clear how the vi-
rus can penetrate the hematoencephalic bar-
rier (Wang et al., 2017b; Xia et al., 2018). 
However, an alternative protein, the NS1’, 
has been reported in ZIKV (specifically Asian 
lineage) and other neuroinvasive Flavivirus. 
This suggests that this protein may be in-
volved with the viral neurotropism and there-
fore with its neuroinvasiveness (Tambonis et 
al., 2017).  
As a consequence about the previously re-
viewed information, it is possible to establish 
that the NS1 protein of the Flavivirus, induces 
a protective immune response against infec-
tion; it is an important immunogen in the viral 
infection course (Chen et al., 2017), and a bi-
omarker for the diagnostics of dengue, zika 
and chikungunya infections (Cecchetto et al., 
2017). 
The NS2 protein, is encoded by the NS2 
region of the Flaviviridae genome. The NS2 
protein can be also processed into the matured 
proteins such as NS2A and NS2B (Chen et al., 
2017). The NS2A is a 226 amino acid long 
hydrophobic protein, that is inserted in the 
membrane and interacts specifically with neg-
atively charged phospholipids. This protein 
contains some transmembrane domains and is 
associated with the membrane of host endo-
plasmic reticulum (RE). It is involved in the 
evasion of the immune response since it sup-
presses Interferon β transcription (IFN-β), 
and as a result, the interferon response, which 
is one of the host’s first lines of defense. The 
NS2A is required for the processing of NS1 
containing specific recognition motifs tar-
geted by specific proteases. It is also involved 
in the virion assembly and the synthesis of vi-
ral RNA. For example, in the case of YFV, a 
Lys-to-Ser mutation at position 190 in NS2A 
blocked the production of virus particles 
(Leung et al., 2008). Additionally, it has been 
reported that in DENV there are two different 
sets of NS2A molecules, which could be in-
teresting for the development of control strat-
egies (Xie et al., 2015). The functions of 
NS2A are related to the membrane structure 
and orientation, and mainly in both viral RNA 
synthesis and virion assembly (Murray et al., 
2008; Xie et al., 2015). NS2B is an integral 
protein of 14 kDa and is composed of three 
EXCLI Journal 2019;18:988-1006 – ISSN 1611-2156 
Received: September 17, 2019, accepted: October 29, 2019, published: October 31, 2019 
 
 
994 
domains, two transmembrane segments lo-
cated at the N and C terminal regions, and a 
central region of 47 amino acids that acts as 
cofactor for the protease NS3. The complex 
NS2B-NS3 serves as a place for the assembly 
of the replication complex of the flaviviruses 
and modulates both the viral pathogenesis and 
the immune response of the host (Murray et 
al., 2008; Chen et al., 2017). Although the 
functions of NS2A and NS2B proteins are not 
well understood, it is known that in DENV, 
apoptosis is induced by NS2B-NS3 protease 
precursor and NS3 protease, most likely 
through the caspase-8 pathway or NF-κB 
pathway (Uno and Ross, 2018).  
NS3 is an enzyme that shows approxi-
mately 65 % sequence identity between 
DENV, ZIKV, and YFV (Brand et al., 2017), 
therefore is interesting for the development of 
control strategies. The NS3 protein is the sec-
ond largest protein after NS5, and is com-
posed by two regions: the N-terminal region 
that contains a serine protease domain and a 
chymotrypsin protease domain. The C-termi-
nal region that contains both a nucleoside tri-
phosphatase (NTPase) and a RNA helicase 
domain. Serine protease is involved in the 
proteolytic processing of the viral polyprotein 
in three single proteins, as mentioned above, 
and thus plays a central role in the viral repli-
cation cycle. The chymotrypsin protease 
cleaves the viral precursor polyprotein to re-
lease each individual NS protein and the 
NTPase/dependent RNA helicase, which are 
involved in the replication of the genome and 
synthesis of viral RNA (Natarajan, 2010). 
Likewise, DENV-NS2B is required as a co-
factor for NS3 protease activity, for example, 
it has been described that in DENV is respon-
sible for the cleavage between NS2A/2B, 
NS2B3, NS3/4A and NS4B/5 (Chen et al., 
2017). 
DENV NS4 protein is cleaved by the NS3 
host signal protease and peptidase, producing 
mature NS4A and NS4B proteins. This pro-
cess is necessary for the inhibition of the IFN 
signaling pathway, as well as for the viral rep-
lication process (Zou et al., 2015; Chen et al., 
2017). NS4A is a small integral membrane 
protein and it contains four transmembrane 
segments that act as a scaffold for the replica-
tion complex. It has been proposed that NS4A 
leads to membrane modifications and plays an 
important role in the formation of structures 
derived from the host’s membrane. The N-ter-
minal region of NS4A interacts specifically 
with curved membrane regions. It is an essen-
tial component of the viral replication cycle 
because it interacts directly with the vimentin 
protein of the cytoskeleton, an event that is 
necessary for the correct localization of the 
replication complex in the perinuclear region 
(Teo and Chu, 2014). On the other hand, the 
protein NS4A is involved in the induction of 
autophagy as a mechanism for infection 
(McLean et al., 2011). NS4B is formed by 
three C-terminal trans-membrane segments 
and is involved in blocking the signaling 
transduction of the IFN-α/β, as well as modu-
lating the function of NS3 helicase. In YFV 
and WNV, NS4B and STAT1 show cytoplas-
mic localization, and can inhibit the ‘Inter-
feron Stimulated Response Element’ activa-
tion mediated by IFNβ (Nemésio et al., 2012; 
Uno and Ross, 2018). Even though the NS4B 
protein is highly conserved among the DENV 
serotypes, mutations in the NS4B of YFV can 
modulate its neuro-invasion capacity, as well 
as its neuro-virulence (Zmurko et al., 2015). 
During Zika infection, NS4A and B are in-
volved in the induction of autophagy in the fe-
tal neural stem cells leading to defective neu-
rogenesis (Liang et al., 2016). 
Finally, NS5, a 104 kDa protein is en-
coded by the C terminus of Flavivirus ge-
nome. It is highly conserved among the Fla-
vivirus, with a homology of about 68 % be-
tween DENV, ZIKV and YFV (Potisopon et 
al., 2014; Brand et al., 2017). NS5 is com-
posed of two domains: the methyltransferase 
domain, indispensable for the formation of 
the CAP structure of the viral genome, and the 
RNA-dependent RNA polymerase domain, 
which is necessary for the RNA genome rep-
lication process. The NS5 protein of the Fla-
vivirus can inhibit the IFN signals during the 
infections caused by DENV, YFV, ZIKV, and 
HCV, in order to evade innate immunity; this 
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is achieved through the interaction with 
STAT2 protein or by modulating RNA splic-
ing within the host cell (Murray et al., 2008). 
DENV infected cells show localization of 
NS5 protein mainly in the nucleus; this may 
be related to the modulation of the cytokine 
gene expression (El Sahili and Lescar, 2017). 
The NS3 protein initially cleaves the NS5 in 
HCV, producing the NS5A and NS5B mature 
proteins. NS5B is an RNA-dependent RNA 
polymerase involved in the viral replication, 
with a terminal nucleotide transferase activity 
using uridine triphosphate as a substrate. Be-
cause the NS5 is a highly conserved protein 
among Flavivirus, and its important role dur-
ing the viral replication and evasion of the 
host immune system, has led to the proposal 
of the NS5 as a target for the development of 
antivirals against Flavivirus infections (El 
Sahili and Lescar, 2017; Shi and Gao, 2017).  
 
Alphaviruses 
The Alphavirus genus, consisting of about 
29 virus species, is characterized by an icosa-
hedral symmetry and a genome that consists 
of a positive sense single-stranded RNA of 
approximately 11.8 Kb length. This ssRNA is 
composed of two open reading frames 
(ORFs), the one on the 5' end produces non-
structural proteins (nsP1-4), and the second 
one at the 3' end that produces five structural 
proteins called: capsid protein (C), envelope 
glycoproteins (E1 and E2), and two small 
cleavage products (E3 and 6K). The 5' end of 
the CHIKV genome also shows a 7-methyl-
guanosine cap (Figure 1) (Jose et al., 2009; 
Shi and Gao, 2017). 
The structural proteins are required for en-
try, assembly, and budding steps. These pro-
teins are processed as a polyprotein, which are 
cleaved by capsid and host proteases into C, 
E3, E2, 6K, and E1 proteins. The proteins E3 
and E2 have pE2 as intermediary compound, 
cleaved by host furin protease. The N-termi-
nal domain of E3 is an uncleaved leader pep-
tide for E2, which may help shield fusion pep-
tide in E1 during egress. The E1 glycoprotein 
mediates the virus-membrane fusion. The E2 
mediates the binding to the receptors and at-
tachment factor on the cell membrane and is 
the major target for neutralizing antibodies. 
At low pH E1 and E2 dissociated in the endo-
some, which trigger the fusion of the viral and 
endosomal membranes, thus releasing the vi-
ral genome into the cytoplasm (Li et al., 
2010). It has been reported that E2 residue 82, 
in CHIKV, is determinant of glycosaminogly-
can utilization and therefore, in the viral en-
try, this may have had an impact on the atten-
uation of the vaccine strain 181/25 (Silva et 
al., 2014). 
Besides, the protein 6K acts as a leader 
peptide for E1 and facilitates particle morpho-
genesis, and are involved in the formation of 
viroporins that play a role in the release of vi-
rus progeny, the intracellular trafficking of 
glycoprotein and the permeability of the 
membrane. The transframe protein, generated 
by ribosomal frame shifting, shares N-termi-
nus with 6K, which is also considered as a pu-
tative ion channel that may enhance particle 
release. E1 in CHIKV is a 436 aa type II fu-
sion protein, through fusion of viral envelope 
and endosomal cellular membrane (Jose et al., 
2009; Bautista-Reyes et al., 2017). 
In turn, capsid protein has two domains: 
The N-terminal RNA binding domain and the 
C-terminal protease domain. The N-terminal 
region is indispensable for binding to RNA 
genome, C protein multimerization and its 
subsequent nuclear/cytoplasmic translocat-
ion. About the nuclear translocation is known 
that induces host cell transcriptional blockade 
in encephalitic alphaviruses, however it is not 
clear in arthritogenic alphaviruses yet (Taylor 
et al., 2017), however mutation of a nucleolar 
localization sequence in the CHIKV N-termi-
nal region of capsid protein, is involved in vi-
ral attenuation. Thus, this motive capsid pro-
tein is a target for the development of vac-
cines (Taylor et al., 2017; Yap et al., 2017a; 
Sharma et al., 2018).  
On the other hand, the alphaviruses pre-
sent four non-structural proteins (nsP), which 
are well characterized in CHIKV (Pietilä et 
al., 2017; Silva and Dermody, 2017): 
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 nsP1 have both guanine-7-methyltransfer-
ase and guanylyltransferase activities, thus 
is responsible for the addition of the 5´Cap 
to viral genomic and subgenomic RNAs, a 
step necessary to avoid the viral RNA deg-
radation and for its subsequent translation. 
This protein is also involved in anchoring 
the replications complexes to the cellular 
membranes maybe through interaction with 
anionic phospholipids from the membrane 
(Abu Bakar and Ng, 2018; Mutso et al., 
2018).  
 The master regulator of the Alphavirus cy-
cle, the nsP2, which consists of 798 aa. In 
the c-terminal region shows a papain-like 
cysteine protease, which is required to pro-
cess P1234 polyprotein into mature non-
structural proteins, act as a RNA triphospha-
tase involved in viral RNA capping reac-
tions, as a nucleotide triphosphatase supply 
the RNA helicase activity. Mature nsP2, in 
its N-terminal region contains a helicase do-
main, catalyzes the cleavages between the 
nonstructural proteins, and an inactive RNA 
methyltransferase-like domain. The C-ter-
minal subdomain is an 5-adenosyl-L-methi-
onine-dependent (SAM) RNA methyltrans-
ferase domain with no enzymatic function 
(Rana et al., 2017; Mutso et al., 2018). Virus 
with mutations in this nsP2 protein are una-
ble to produce cytopathic effect (Shin et al., 
2012).  
 nsP3, which consists of 530 aa, have three 
domains: the N-terminal macro domain, the 
central zinc-binding domain and the C-ter-
minal hypervariable domain (HVD). This 
protein is involved in the negative sense and 
subgenomic viral RNA synthesis and is a 
component of the viral RNA replicase com-
plex and has been associated with the neuro-
virulence of some alphavirus. The N-termi-
nal domain conserved among alphaviruses, 
which exhibits both ADP-ribose and RNA 
binding activities, and also dephosphorylate 
ADP-ribose-1′′-phosphate and have de-
ADP-ribosylating activity. The central zinc-
binding domain is also conserved among al-
phaviruses, it is involved in the RNA repli-
cation, however it is no yet cleared. The hy-
pervariable domain shows variability even 
between closely related alphaviruses, being 
indispensable for alphavirus replication 
(Götte et al., 2018). Mutations in nsP3 have 
been associated with defects in the initiation 
of minus-strand synthesis or subgenomic 
RNA synthesis (Mutso et al., 2018), and the 
degradation of this protein seems to be in-
volved in the upregulation of nsP4 levels 
(Götte et al., 2018). 
 The highly conserved protein nsP4 has a ho-
mology greater than 50 % among alpha-
viruses. This protein consists of 611 aa, is a 
RNA-dependent RNA polymerase and ter-
minal adenosine transferase, responsible for 
synthesis of different viral RNAs and adding 
(and repair) the poly (A) tails to positive 
strand RNAs, essential steps to the virus rep-
lication (Tomar et al., 2006; Mutso et al., 
2018).  
 
REPLICATION OF FLAVIVIRUS  
AND ALPHAVIRUS 
After an infected mosquito feed on a 
mammalian host, the viral particles are re-
leased in the bloodstream and then infect the 
white cells; the specific binding site is located 
in the E protein of the virus (Allison et al., 
1995; Welsch et al., 2009). 
Both flaviviruses and alphaviruses enter 
cells through clathrin-coated vesicles or spe-
cific receptors on the cell membrane. How-
ever, in all the cases the membrane fusion 
process is triggered by the low pH of the en-
dosome. E and E1 proteins, from Flavivirus 
and Alphavirus respectively, share several 
common characteristics and suffer, with small 
differences, the same changes to promote the 
membrane fusion between the virus and the 
target cell. The E and E1 suffer a significant 
conformational change that promote the DIII 
to move close the fusion loop, the DIII do-
main maintain the link of the fusion and the 
transmembrane domains. After the conforma-
tional change and reorganization of E and E1 
protein, the DII domain is exposed and allows 
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it to interact with the target membrane and 
promote the fusion.  
 
Flavivirus replication mechanism 
Once the flaviviruses are in the endo-
somes; the acidic pH triggers the assembly of 
E trimers that leads to the release of the nu-
cleocapside into the cell cytoplasm. Subse-
quently the capsid–RNA complex leaves the 
endosome, presumably through the pores 
(Figure 2). The RNA produces a polyprotein, 
which is directed to the endoplasmic reticu-
lum, where it is processed by cellular and vi-
rus-derived proteases into structural and non-
structural proteins (Rodenhuis-Zybert et al., 
2010; Garcia-Blanco et al., 2016). 
Figure 2: Life cycle of DENV in infected cells. The viral particles are released in the bloodstream; 
they then infect the white cells; the specific binding site of the virus is located in the E protein; it interacts 
with the specific superficial receptors of the host’s cell, for example, mannose receptor, HSP90, HSP70, 
GAG heparin sulfate, DC-Sign, and TIM/TAM (Perera-Lecoin et al. 2013);  this initiates the entry of the 
virus, endocytosis mediated by receptors is the primary route by which flavivirus are internalized. A 
summary of the steps that occur during the infection process from the entry of virus into the cell up to 
the release of new mature viral particles is as follows: 
 The entry into the cell is achieved by endocytosis within clathrin-coated vesicles. 
 The acidification of endosomes leads to insertion of the E protein into the endosomal membrane, the fusion of the viral 
envelope, and endosomal membrane releases nucleocapsid into the cytosol.  
 After the nucleocapsid is uncovered, the viral RNA is translated as a single polyprotein, translocated across the host 
endoplasmic reticulum membrane. 
 Particles that have budded from the ER are then processed by carbohydrate addition and modification, as they proceed 
through the Golgi membrane system. It is likely that transportation into the trans-Golgi network requires the presence 
of the glycosylated prM protein.  
 The mature viral particles are released by exocytosis and can infect more cells.  
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The E and prM proteins are glycosylated 
and then the NS proteins trigger viral genome 
replication. Several modifications of viral 
RNA are observed during its replication, such 
as methylation, which protects the RNA from 
quick degradation and manages the transcrip-
tion efficiency. This modification is necessary 
for the formation of the virions and it is de-
tected in different flaviviruses (Yap et al., 
2017b).  
The coupling of protein synthesis, RNA 
synthesis, and the virion assembly on mem-
branous structures assures that the newly syn-
thesized RNA genome can be associated with 
C protein, thus initiating the assembly pro-
cess. RNA encapsidation initiates the budding 
of particles into the ER-derived membrane 
vesicles, formation of which is believed to be 
induced by prM/E heterodimers (Welsch et 
al., 2009; Rodenhuis-Zybert et al., 2010). 
These immature virions that have budded into 
the ER, are then processed by carbohydrate 
addition and modification as they proceed 
through the Golgi membrane system. It is 
likely that the transportation through the 
trans-Golgi network requires the presence of 
the glycosylated prM protein, which is ob-
tained after prM/E heterodimers dissociation. 
prM is cleaved, just prior virus release, by the 
host-encoded furin, into a pr peptide and a 
membrane-associated M protein, allowing for 
the cleavage of E proteins and thus helping in 
the virion maturation. Virions follow the exo-
cytosis pathway and are released into the ex-
tracellular space by fusion of vesicles contain-
ing virions with the plasma membrane 
(Keelapang et al., 2004; Rodenhuis-Zybert et 
al., 2010). Mature viruses are released from 
the host cell by exocytosis and the new mature 
virus can infect more cells (Suwanmanee and 
Luplertlop, 2017).  
 
Alphavirus replication mechanism 
After internalization of alphaviruses in 
endosomes, the reduction in pH level, due to 
the H+ pump, leads to the conformational re-
organization of viral heterodimer E1-E2, re-
leasing E1 as a result. Thereby, the domain II 
is exposed and the viral particle fuses with the 
membrane of the host cell (Schuffenecker et 
al., 2006). The E3 protein interacts with the 
E2 protein, stabilizing a region called the 
“acid-sensitive region”, indirectly facilitating 
the activation of E1 that is required for the 
membrane fusion (Sjöberg et al., 2011). The 
endosome releases the nucleocapsid and the 
RNA genome; both coupled by interaction of 
the major RNA subunit 60S with the signal 
protein of the nucleocapsid. This mechanism 
is highly conserved among alphaviruses 
(Sjöberg et al., 2011) (Figure 3). 
Subsequently the genome is translated to 
generate the non-structural and structural pro-
teins. The non-structural proteins (nsP1-4) 
and their precursors are necessary for the rep-
lication of the viral RNA. The five structural 
proteins (C, E3, E2, 6K, E1) and their precur-
sors are necessary for viral encapsidation and 
budding. Viral replication occurs in the host 
cytoplasm in close connection with the Golgi 
apparatus (Thiberville et al., 2013). 
The non-structural proteins (nsP1-4) are 
translated as polyprotein: P123 and P1234 (in 
smaller proportion) (Solignat et al., 2009). 
First nsP4 is cleaved off from nsP123 to form 
the replication complex, which produces the 
negative strand (Barton et al., 1991); this is 
detected during the early phases of CHIKV 
replication. When nsP123 concentration is 
enough to support an efficient reaction, it is 
cleaved into mature nsP1, nsP2, nsP3, and 
nsP4 (Solignat et al., 2009). These proteins, 
together with host cell proteins, act as a plus-
strand RNA replicase, which produces the 
26S sub-genomic plus-strand RNA using the 
negative-strand RNA as a template (Shirako 
and Strauss, 1994). This 26S sub-genomic 
RNA encodes the polyprotein precursor for 
structural proteins, which is cleaved to yield 
C, pE2, 6K, and E1 by an autoproteolytic ser-
ine protease (Solignat et al., 2009). C and 6K 
proteins are accumulated in cell’s cytoplasm 
for the formation of new nucleocapsids, 
which are assembled with a copy of the viral 
genome by means of proteolytic cuts. E3, E2, 
and E1 proteins, are post-transcriptionally 
modified and initiate their glycosylated in the 
endoplasmic reticulum and translocated to the 
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Golgi apparatus and pack in vesicles to be de-
livered in the cell membrane. When the nucle-
ocapsid interacts with the glycoproteins accu-
mulated in the cell’s membrane, the viral par-
ticles under the maturation process acquire a 
membrane envelope and then they are finally 
released by exocytosis (Bautista-Reyes et al., 
2017). 
 
Flavivirus and alphavirus treatments 
To date there is not a specific treatment to 
eradicate the infection by arboviruses, the 
treatment choice is basically to reduce the 
symptoms, although, the viral replication is 
not affected. A vaccine for DENV has been 
recently implemented to be used in people 
aged 9 to 45 years living in endemic areas 
(Barrows et al., 2016). However, there are 
limitations to the application of this vaccine, 
since it has been reported that people who 
have never had dengue are more susceptible 
to developing a more severe disease, if they 
are vaccinated. In addition, the Philippine 
government suspended the use of the vaccine 
after the death of three people due to dengue 
despite being vaccinated (Dyer, 2017). There-
fore, there is no vaccine available for the 
treatment of DENV (Lim et al., 2013). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Life cycle of CHIKV in infected cells. The majority of the cells that get infected by CHIKV 
express glycosaminoglycans that apparently act as a virus-cell binding factor, increasing infectivity. 
Once endocytosed inside the endosome, there is a reduction in pH level. Then the endosome releases 
the nucleocapsid and the genome; the nsP123 precursor is translated from the viral genome and it binds 
to free nsP4 along with some host proteins to form the replication complex. When nsP123 concentration 
is enough to support an efficient reaction, it is cleaved into mature non-structural proteins: nsP1-4. These 
proteins together with the host cell proteins act as plus-strand RNA replicase. The 26S sub-genomic 
RNA encodes for the polyprotein precursor for structural proteins, which is cleaved by an autoproteolytic 
serine protease in order to yield C, pE2, 6K, and E1. The C and 6K proteins are accumulated in the 
cell’s cytoplasm for the formation of new nucleocapsids. The E3, E2, and E1 proteins are glycosylated 
at endoplasmic reticulum and then are sent, through the Golgi apparatus, in vesicles to the cell mem-
brane, where can interact with the nucleocapsid, resulting in the viral particles maturation to be finally 
released by exocytosis. 
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In the middle of this bleak panorama, sev-
eral candidates for arbovirus vaccines have 
been proposed, however, these are only tested 
in animal models. For example, Weger-Lu-
carelli and colleagues (2014) describe the 
construction and characterization of a modi-
fied Ankara virus-based vaccine, and express-
ing CHIKV E3 and E2 proteins, the authors 
demonstrated that the vaccine protected dif-
ferent type of mice against CHIKV infection 
(Weger-Lucarelli et al., 2014). Prow and col-
leagues, described a single-vector construct-
based vaccine, that expresses the prME pro-
tein of zika virus and the polyprotein con-
formed by C-E3-E2-6K-E1 proteins of 
chikungunya virus, having as a result that a 
single dose of the vaccine in different type of 
mice, can elicit neutralizing antibodies, there-
fore, it provides protection against both vi-
ruses (Prow et al., 2018).  
The use of natural products, as therapeutic 
tools, is an ancestral practice in different cul-
tures. According to WHO 80 % of the popu-
lation of some countries from Africa and Asia 
depend on the use of traditional medicines to 
deal with some diseases (Oliveira et al., 
2017). The neglected disease, as some of the 
mentioned in this work, required the urgent 
description of new molecules with antiviral 
capacity for their treatment, as a sample; there 
are multiple articles that describe the use, in 
vitro, of natural products as inhibitors of some 
arboviruses infection.  
For instance, a compilation of studies, 
from 1997 to 2012, describes the use of natu-
ral products of 31 species (that belong to 24 
different plant families). Those studies in-
clude the analysis of species as Cladosiphon 
okamuranus, Leucaena leucocephala, Mi-
mosa scabrella, Tephrosia madrensis, Cryp-
tonemia crenulata, Gymnogongrus grif-
fithsiae, Meristiella gelidium, among others. 
From which, were isolated approximately ten 
phytochemicals: as Fucoidan, Galactoman-
nan, Glabranine, 7-O-methyl-glabranina, Ga-
lactane, hyperóeside, Kappa carragenane, 
Zosterice acid, 4-hydroxypanduratine A, pan-
duratine A. These compounds belong to vari-
ous kinds of chemical families such as: poly-
saccharides sulfated, flavonoids, quercetine 
and natural compounds of chalcone, which 
have anti-proliferative activity against dengue 
virus (Abd Kadir et al., 2013).  
In relation to zika, curcumin, a common 
food additive, was considered capable of re-
ducing ZIKV infectivity by preventing the vi-
rus binding to cells, without showing adverse 
effects on cell viability (Sharma et al., 2018). 
Quercetine, a flavonoid present in fruits, veg-
etables, leaves and grains, inhibits the enzy-
matic activity of NS2B-NS3 in a dose-de-
pendent manner. Also, it has been reported 
that commercially available quercetine inhib-
its ZIKV protease with an IC50 of 26.0 ± 0.1 
μM (Mounce et al., 2017). Although all these 
studies are promising, more researches are 
still needed, in order to validate them as ther-
apeutic tools.  
Despite the fact the use of natural products 
to inhibit different viruses has proven to be 
feasible and with good results in vitro. The 
knowledge of the biology of Flavivirus and 
Alphavirus have accelerated the discovery of 
selective targets to attack, with possibilities to 
inhibit their replication. In the case of ZIKV 
these proteins are well known as possible tar-
gets: NS2B-NS3 protease, NS3 helicase, NS5 
polymerase, NS5 methyltransferase, the en-
velope and the capsid. To DENV, the research 
has been focused on multifunctional enzymes 
NS3, NS5 and the capsid protein.  In the case 
of CHIKV one of the most suitable targets is 
the cysteine protease domain nsP2. All these 
proteins were selected as target because of 
their important role in the respective viral cy-
cle replication. 
However, Roy et al. (2017) assessed a set 
of 9 natural products against zika virus, their 
results show that 6 of these compounds may 
inhibit the virus replication and have interac-
tion as no competitive inhibitors of the NS2B-
NS3 protein. In another study, that involved 
over 1350 extracts of plants as inhibitors of 
the DENV polymerase using the domain 
RdRp of DENV-2 NS5, 49 extracts showed 
an inhibition of at least 80 % infection, and 
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one of these extracts, obtained from Crypto-
carya chartacea exhibited 90 % inhibition at 
a concentration of 10 µg/ml. Subsequent pu-
rification of this extract reported 10 com-
pounds: 1 pinocembrin and 9 chartaceone de-
rivatives of pinocembrin. The pinocembrin 
did not show antienzymatic activity, however 
all the chartaceone derivatives showed differ-
ent values of inhibition (Allard et al., 2011).  
Pohjala et al. evaluated 356 (123 natural 
products and 233 clinical approved drugs) as 
inhibitors of CHIKV infection, using a stable 
replication cell line. Their results showed that 
under experimental conditions the flavonoids 
apigenin, chrysin, naringenin and silybin, 
were the most actives against CHIKV 
(Pohjala et al., 2011). The Harringtonine, a 
natural product obtained from Cephalotaxus 
sp, shows a high antiproliferative activity 
against CHIKV, with EC50 of 0,24 µM and a 
very low cytotoxicity. These results suggest a 
possible inhibition at early stages of viral rep-
lication; additionally this compound was able 
to inhibit the replication of Sindbis virus too, 
suggesting a possible inhibition of other al-
phaviruses (Kaur et al., 2013). In accordance 
with the previously indicated and, also, in-
cluding other authors who have made relevant 
contributions on this subject, Table 1 shows 
the main natural products that have been eval-
uated against Flavivirus and Alphavirus. 
 
CONCLUDING REMARKS 
Arbovirus, such as dengue, zika, and 
chikungunya viruses, are an important threat 
to global public health, especially in subtrop-
ical and tropical regions where these are 
maintained due to the peculiar environmental 
conditions which favor the development and 
proliferation of their main vectors, the Aedes 
aegypti and Aedes albopictus. The vector con-
trol strategies have failed, mainly due to in-
secticides resistance (Suwanmanee and 
Luplertlop, 2017); in addition to this, there are 
factors such as the low coverage and effi-
ciency of basic hygiene services in develop-
ing countries. This environment facilitates a 
favorable and permanent culture medium for 
the cyclical prevalence of these diseases that 
are still present in most Latin American coun-
tries (PAHO-CHA-IR, 2016; Higuera and 
Ramírez, 2019). 
 
 
Table 1: Summary about some naturals products which has been evaluated against Flaviviruses and 
Alphaviruses 
Compound EC50 Target/pathogen References 
Epigallocatechingallate 21.4 µM Env/Zika Carneiro et al., 2016  
Nanchanmycin 0.1 µM ?  / Zika Rausch et al., 2017  
Myricetin 1.3 µM NS2b-NS3 protease/Zika Roy et al., 2017  
Quercetin 2.4 µM NS2b-NS3 protease/Zika Roy et al., 2017  
Luteolin 2.7 µM NS2b-NS3 protease/Zika Roy et al., 2017  
Isohamnetin 15.5 µM NS2b-NS3 protease/Zika Roy et al., 2017  
Curcumin 3.5 µM NS2b-NS3 protease/Zika Roy et al., 2017  
NSC135618 ---- NS2B-NS3 protease/Zika DENV Brecher et al., 2017  
Panduratin A 400 ppm  
(99.8 % inhibition) 
NS2B-NS3 protease/DENV Kiat et al., 2006  
4-hydroxypanduratin A 400 ppm  
(99.8 % inhibition) 
NS2B-NS3 protease/DENV Kiat et al., 2006  
Harringtonine 0.24 µM Early stages of replication cy-
cle/CHIKV 
Kaur et al., 2013  
Tigocherin A 12.7 µM 
1.5 µM 
NS5 RdRp/DENV 
Replication CHIKV 
Oliveira et al., 2017  
Tigocherriolide A 3.1 µM 
1.9 µM 
NS5 RdRp/DENV 
Replication CHIKV 
Oliveira et al., 2017  
Tigocherriolide B 16 µM 
3.9 µM 
NS5 RdRp/DENV 
Replication CHIKV 
Oliveira et al., 2017  
Chloroquine 17.2 µM Internalization CHIKV Khan et al., 2010  
Mycophenolic acid 0.1 µM  
(using a MOI of 0.01) 
IMPDH/CHIKV Khan et al., 2011  
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The discovery and/or design of new med-
icines to treat some of the diseases caused by 
arbovirus are a great challenge, but also an ur-
gent need. To date there is no specific treat-
ment for infection caused by DENV, ZIKV, 
CHIKV and other human-related infections 
caused by arbovirus. The development of a 
vaccine is still ongoing, but that directed 
against DENV has not shown safety results. 
Despite the enormous difficulties for the de-
velopment of new vaccines that can be effec-
tive against communicable diseases, in the 
present case of arboviral origin, this strategy 
continues being the most important alterna-
tive to prevent and counteract the negative 
impact on global public health of the above 
pathologies. 
On the other hand, the existence of some 
promising natural products and their possible 
therapeutic targets of action were stated. 
Highlighting that for DENV and ZIKV the 
NS2B.NS3 protease coincides as a potential 
target, further Tigocherin A and Tigocherrio-
lide A showed potential inhibitory activity for 
DENV, having as a possible target of action 
the NS5RdRp protein. Nevertheless, in the 
case of CHIKV still is not clear a possible ac-
tion target, however, it is known that the first 
stage of the replication cycle is the most sus-
ceptible to the extracts tested (Khan et al., 
2011). 
Despite the extensive knowledge of the 
molecular structure and replication mecha-
nisms of these arboviruses, there are still 
many gaps in what we know. Future investi-
gations are necessary to elucidate many mo-
lecular aspects that can give us insights into 
the viral emergence mechanisms, cellular 
pathogenesis, and host-virus interactions. 
These would be helpful for the development 
of urgent control strategies and for improving 
their effectiveness.  
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